Enhancing axonal regeneration by administration of DAIDZEIN, a FDA approved phytoestrogen
Funded in: 2009, 2010, 2011
Back to overview
After spinal cord injury, molecular STOP signs contribute to the failure of regeneration of injured nerve fibres. Among others, in the CNS are myelin-associated proteins, such as myelin-associated glycoprotein (MAG). Daizein, a FDA approved drug has been shown to overcome this inhibition in vitro. This project aims on a first step at confirming the in vitro results. On a second step it addresses the question whether daidzein promotes regeneration in vivo.
If this will be achieved the underlying mechanisms of action should be indentified. If successful, this project would then allow daizein to be translated into a clinical trial for acute injured patients in order to actively promote nerve regeneration.